Core Insights - Society Pass Incorporated (SOPA) reported a quarterly loss of $0.89 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -1,171.43% [1] - The company's revenues for the quarter ended September 2025 were $1.38 million, missing the Zacks Consensus Estimate by 42.5% and down from $1.68 million a year ago [2] - The stock has increased by approximately 87.1% since the beginning of the year, outperforming the S&P 500's gain of 14.6% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.07 on revenues of $2.4 million, and for the current fiscal year, it is -$0.42 on revenues of $8.8 million [7] Industry Context - The Technology Services industry, to which Society Pass Incorporated belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Core Insights - Marchex (MCHX) reported break-even quarterly earnings per share, missing the Zacks Consensus Estimate of $0.01, compared to a loss of $0.01 per share a year ago, resulting in an earnings surprise of -100.00% [1] - The company posted revenues of $11.51 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 3.49%, and down from $12.55 million year-over-year [2] - Marchex shares have declined approximately 8.6% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Marchex's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $11.33 million, and for the current fiscal year, it is -$0.01 on revenues of $46.31 million [7] Industry Context - The Internet - Services industry, to which Marchex belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8]

Core Insights - Globant reported quarterly earnings of $1.53 per share, slightly missing the Zacks Consensus Estimate of $1.54 per share, and down from $1.63 per share a year ago, indicating an earnings surprise of -0.65% [1] - The company posted revenues of $617.14 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.31% and showing a year-over-year increase from $614.67 million [2] - Globant's stock has underperformed significantly, losing about 71.2% since the beginning of the year compared to the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.55 on revenues of $605.12 million, while for the current fiscal year, the estimate is $6.12 on revenues of $2.45 billion [7] - The estimate revisions trend for Globant was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Internet - Software and Services industry, to which Globant belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - The Oncology Institute, Inc. reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, but an improvement from a loss of $0.18 per share a year ago [1] - The company achieved revenues of $136.56 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 11.71% and showing a significant increase from $99.9 million in the same quarter last year [2] - The stock has increased approximately 1010% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, The Oncology Institute has not surpassed consensus EPS estimates, indicating challenges in meeting earnings expectations [2] - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $127 million, and for the current fiscal year, it is -$0.55 on revenues of $473.45 million [7] Market Outlook - The company's earnings outlook and management's commentary on the earnings call will be crucial for understanding future stock movements [3][4] - The Zacks Rank for The Oncology Institute is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] - The Medical Services industry, to which The Oncology Institute belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, which may impact the stock's performance [8]

Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.26, delivering a surprise of -1200%.Over the last four quarters, the company has no ...

分组1 - Cadiz reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -11.11% [1] - The company posted revenues of $4.15 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 6.39%, and showing an increase from $3.22 million year-over-year [2] - Over the last four quarters, Cadiz has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] 分组2 - The stock has underperformed, losing about 11.5% since the beginning of the year, while the S&P 500 gained 16.5% [3] - The current consensus EPS estimate for the coming quarter is $0.54 on revenues of $3.9 million, and for the current fiscal year, it is $0.24 on revenues of $14.9 million [7] - The Agriculture - Operations industry, to which Cadiz belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - Star Equity Holdings reported quarterly earnings of $0.02 per share, significantly missing the Zacks Consensus Estimate of $0.32 per share, representing an earnings surprise of -93.75% [1] Financial Performance - The company posted revenues of $47.96 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.99%, compared to revenues of $36.85 million a year ago [2] - Over the last four quarters, Star Equity Holdings has surpassed consensus revenue estimates two times [2] Stock Performance - Star Equity Holdings shares have declined approximately 22% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $0.09 on revenues of $62.05 million, and $0.28 on revenues of $175.14 million for the current fiscal year [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock movements [6] Industry Context - The Diversified Operations industry, to which Star Equity Holdings belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Fate Therapeutics reported a quarterly loss of $0.27 per share, which is better than the Zacks Consensus Estimate of a loss of $0.29, and an improvement from a loss of $0.40 per share a year ago [1][2] - The company achieved a revenue of $1.74 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 104.82%, although this is a decline from $3.07 million in the same quarter last year [3] Financial Performance - The earnings surprise for the quarter was +6.90%, and over the last four quarters, the company has consistently surpassed consensus EPS estimates [2] - Fate Therapeutics has also topped consensus revenue estimates four times in the last four quarters [3] Stock Performance - Since the beginning of the year, Fate Therapeutics shares have declined by approximately 37%, contrasting with a 16.5% gain in the S&P 500 [4] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $0.85 million, and for the current fiscal year, it is -$1.14 on revenues of $4.38 million [8] - The outlook for the Medical - Biomedical and Genetics industry is relatively strong, ranking in the top 35% of over 250 Zacks industries, which may positively influence stock performance [9]

Core Viewpoint - Sunrise Realty Trust, Inc. reported quarterly earnings of $0.31 per share, matching the Zacks Consensus Estimate and showing an increase from $0.25 per share a year ago [1]. Financial Performance - The company posted revenues of $6.06 million for the quarter ended September 2025, which was 2.32% below the Zacks Consensus Estimate, compared to $3.18 million in the same quarter last year [2]. - Over the last four quarters, Sunrise Realty Trust has surpassed consensus EPS estimates two times and topped consensus revenue estimates only once [1][2]. Stock Performance - Shares of Sunrise Realty Trust have declined approximately 33.3% since the beginning of the year, while the S&P 500 has gained 16.5% [3]. - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $6.56 million, and for the current fiscal year, it is $1.23 on revenues of $23 million [7]. - The outlook for the Real Estate - Operations industry, to which the company belongs, is currently in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8].

GoHealth (GOCO) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $3.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +90.78%. A quarter ago, it was expected that this company would post a loss of $2.6 per share when it actually produced a loss of $1.23, delivering a surprise of +52.69%.Over the last four quarters, the company has surpassed co ...